In preclinical studies, when IGFBP-2 was added to ovarian cancer cells, increased cell proliferation was noted and multiple MAP kinase signaling pathways were activated including Raf, MEK, ERK1/2, and Elk-1 [55]. Here, IGFBP2 is linked to ovarian carcinoma.